Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 4

2(28.6%)

N/A

1(14.3%)

7Total

Phase 1(4)

Phase 4(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07390929Not ApplicableWithdrawn

Clinical Trial Study on the Improved New Method of Acupotomy for AS

Role: collaborator

NCT04150835Phase 4Unknown

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Role: collaborator

NCT04003168Phase 1Unknown

Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT04303520Phase 1Unknown

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Role: lead

NCT02728180Phase 4Unknown

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

Role: collaborator

NCT03093168Phase 1Unknown

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Role: lead

NCT02685670Phase 1Unknown

Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma

Role: lead

All 7 trials loaded